A trace map on higher scissors congruence groups

Cut-and-paste $K$-theory has recently emerged as an important variant of higher algebraic $K$-theory. However, many of the powerful tools used to study classical higher algebraic $K$-theory do not yet have analogues in the cut-and-paste setting. In particular, there does not yet exist a sensible notion of the Dennis trace for cut-and-paste $K$-theory. In this paper we address the particular case of the $K$-theory of polyhedra, also called scissors congruence $K$-theory. We introduce an explicit, computable trace map from the higher scissors congruence groups to group homology, and use this trace to prove the existence of some nonzero classes in the higher scissors congruence groups. We also show that the $K$-theory of polyhedra is a homotopy orbit spectrum. This fits into Thomason's general framework of $K$-theory commuting with homotopy colimits, but we give a self-contained proof. We then use this result to re-interpret the trace map as a partial inverse to the map that commutes homotopy orbits with algebraic $K$-theory.Comment: 32 pages, 3 figures. Revision of the paper previously entitled "A Farrell--Jones isomorphism for $K$-theory of polyhedra.

First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER

Temsirolimus has long been the only approved first-line standard of care (SOC) with overall survival (OS) benefit in poor-risk patients with advanced or metastatic renal cell cancer (mRCC). However, tyrosine kinase inhibitors are also commonly used in clinical practice. Pazopanib is an SOC for first-line mRCC treatment, but for poor-risk patients data are scarce. The FLIPPER (First-Line Pazopanib in Poor-Risk Patients with Metastatic Renal Cell Carcinoma) study aimed to assess efficacy and safety of first-line pazopanib in poor-risk mRCC patients. FLIPPER was a single-arm, multicenter, Phase IV trial. Key inclusion criteria were treatment-naive clear cell, inoperable advanced or mRCC, poor-risk according to MSKCC with slight modification, Karnofsky performance status (KPS) >= 60% and adequate organ function. Oral pazopanib 800 mg was given daily. Primary endpoint was the 6-month progression-free survival rate (PFS6). Secondary endpoints included PFS, OS, overall response rate (ORR), duration of response (DOR) and safety. For analysis, descriptive statistics were used. Between 2012 and 2016, 60 patients had been included. Forty-three patients qualified for safety analyses, 34 for efficacy. Median age was 66 years, 64.7% of patients were poor-risk, 82.4% had a KPS <= 70%. PFS6 was 35.3% (95% CI, 19.7-53.5). Median PFS and OS were 4.5 months (95% CI, 3.6-7.8) and 9.3 months (95% CI, 6.6-22.2), respectively. ORR was 32.4% (95% CI, 17.4-50.5), median DOR 9.7 months (95% CI, 1.8-12.4). The most common treatment-related grade 3/4 adverse event reported in 4.7% of patients was hypertension. No treatment-related death occurred. Since pazopanib is active and well tolerated in poor-risk patients with clear cell mRCC, our results support its use as first-line treatment in this setting